# CyDex Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cydex-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Lenexa, US
- Website: www.cydexpharma.com
- Total disclosed funding: $17M
- Latest round: Series B (Aug 17, 2004)
- Investors on record: 5

## About

CyDex Pharmaceuticals, Inc. specializes in developing innovative pharmaceutical solutions aimed at enhancing drug delivery and efficacy. Their focus on improving therapeutic outcomes is central to their operational strategy.CyDex Pharmaceuticals, Inc. operates out of Lenexa, US, and is engaged in the pharmaceutical sector, focusing on advanced drug delivery technologies. The company was acquired by Ligand Pharmaceuticals, Inc. in January 2011 for USD 31.2 million. CyDex has completed a total of four deals, reflecting its strategic growth initiatives in the industry.The company primarily focuses on delivering innovative solutions through its core product offerings, which are designed to address specific challenges faced by its clientele. These offerings encompass advanced drug delivery systems which aim to enhance operational efficiencies and user experiences across various sectors. The company targets businesses in the pharmaceutical market, providing tailored solutions that meet the needs of diverse industries, such as oncology and pain management. With a client base that includes pharmaceutical companies, the end users benefit from the practical applications of the company’s products, which have been well-received since their release in the early 2000s. These solutions not only facilitate improved performance but also aim to foster long-term relationships with clients through consistent support and product development.The revenue model of the company is primarily based on B2B transactions. Transactions typically occur through contracts which enable clients to access the company’s flagship offerings, such as its proprietary drug delivery technologies. Pricing strategies are structured to accommodate various client needs, with different tiers available for specific products or services. This structured approach to pricing and transaction fosters a steady revenue stream, ensuring that the company maintains its market presence and continues to invest in product innovation.CyDex Pharmaceuticals is planning to expand its product line with new drug delivery solutions, with potential launches anticipated by the end of 2023. The company is also focusing on entering new markets within Europe and Asia by 2024. Recent funding from the acquisition by Ligand Pharmaceuticals will support these initiatives, allowing for enhanced research and development efforts.

## Funding rounds

- Series B, Aug 17, 2004, $17M — TVM Capital Life Science, Houston Ventures, SR One, Clariden Bank, Eastman Ventures

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series B
- Houston Ventures (https://capitalatlas.ai/funds/houston-ventures) — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B
- Clariden Bank — Series B
- Eastman Ventures — Series B